Indaptus Therapeutics (NASDAQ:INDP) Trading Up 5.2% – What’s Next?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price rose 5.2% during trading on Friday . The stock traded as high as $1.2350 and last traded at $1.22. 133,112 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 876,766 shares. The stock had previously closed at $1.16.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Indaptus Therapeutics Trading Up 5.2%

The stock has a market cap of $162.56 million, a P/E ratio of -0.19 and a beta of 1.17. The stock’s 50-day moving average is $1.83 and its 200-day moving average is $2.12.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.06% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.